Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trend Innovations Holding Inc. about plans to add a new section

FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti LLC Provides Update of its Investigation of the Officers and Directors of FibroGen Inc. - FGEN


home / news releases / FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA...

  • August, 05 2022 10:50 PM
  • |
  • PR Newswire
  • |
    • FGEN
    • FGEN Quote
    • FGEN Short
    • FGEN News
    • FGEN Articles
    • FGEN Message Board

FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN

PR Newswire

NEW ORLEANS , Aug. 5, 2022 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), provides an update to KSF's continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).

On April 6, 2021 , the Company disclosed that cardiovascular safety data it had previously submitted for the Phase 3 program of its Roxadustat product "included post-hoc changes to the stratification factors." Then, on July 15, 2021 , the FDA's Advisory Committee unequivocally concluded that the Company's own undisclosed, prespecified sensitivity analyses demonstrated that Roxadustat's efficacy over Epogen was inconclusive at best, that it caused "greater rates of some important adverse events [] than even [Epogen]," including a higher rate of death and other major side effects, and that the Committee had voted virtually unanimously against approval for Roxadustat for any patient population, even with a "Black Box" warning.

The Company was subsequently sued in a securities class action lawsuit for failing to disclose material information, violating federal securities laws.

Recently, the court presiding over that case denied the Company's motion to dismiss in part, allowing the case to move forward.

KSF's investigation is focusing on whether FibroGen's officers and/or directors breached their fiduciary duties to the Company's shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of FibroGen shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ( lewis.kahn@ksfcounsel.com ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-fgen/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr. , is one of the nation's premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York , California , Louisiana and New Jersey .

To learn more about KSF, you may visit www.ksfcounsel.com .

Contact:
Kahn Swick & Foti, LLC
Lewis Kahn , Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 3200
New Orleans, LA 70163

SOURCE Kahn Swick & Foti, LLC

Get Email and Text Alerts for (NASDAQ:FGEN)

Get Email and Text Alerts for (NASDAQ:FGEN)

News, Short Squeeze, Breakout and More Instantly...

Tags
  • Healthcare
  • Legal News
  • New York
  • Non-Company
Share This Post

Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Contact the Author

Stock Information

FibroGen Inc Company Name:

FGEN Stock Symbol:

NASDAQ Market:

FibroGen Inc Website:

MENU
FGEN FGEN Quote FGEN Short FGEN News FGEN Articles FGEN Message Board
Get FGEN Alerts

News, Short Squeeze, Breakout and More Instantly...

Ad

Ad

stock market news, trend innovations holding inc about plans to add a n 6310242285372633
RECENT FGEN NEWS
  • FGEN - FibroGen Reports Second Quarter 2022 Financial Results

    Completed enrollment of LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with Duchenne muscular dystrophy 2Q 2022 revenue of $29.8 million, growth of 22% vs. 2Q 2021 Continued significant roxadustat volume growth in China SAN F...

  • FGEN - FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN

    FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & F...

  • FGEN - FibroGen to Report Second Quarter 2022 Financial Results

    SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment comm...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Coins
  • Link Twitter
  • Sign Up
  • Login
  • Contact
x

Ad

KITTEE TRC20 Token Ad

Important Investor Video Alert TREN)

  • TREN - Trend Innovations Holding Inc. about plans to add a new section "Podcasts"

    VILNIUS, LITHUANIA / ACCESSWIRE / August 17, 2022 / Trend Innovations Holding Inc. (OTCQB:TREN) is a company specializing in innovative technologies using artificial intelligence. Thy News application is one of the key projects of the company. Thy News is a mobile application with convenien...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

Follow @marketwirenews

| Facebook

| Telegram

| LinkedIn

| Reddit

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2022 Market Wire News